跳到正文
原文
Medical Xpress·· 24 天前精选AI 评分64

罕见癌症的位置影响生存率,研究显示

Location of rare cancer impacts survival, study suggests

AI 导读

一项研究发现,平滑肌肉瘤在不同部位的生存率存在显著差异,强调了肿瘤位置对疾病风险和治疗方案的重要性。研究还指出,不同部位的肿瘤在生物学上存在差异,可能支持个性化治疗的发展。

推荐理由

研究揭示不同部位的平滑肌肉瘤生存率差异,强调肿瘤位置对治疗方案的影响。

正文
Location of rare cancer impacts survival, study suggests
Characteristics of leiomyosarcoma cases. Credit: JNCI: Journal of the National Cancer Institute (2026). DOI: 10.1093/jnci/djag284

A rare, aggressive cancer, commonly found in the uterus, limbs and abdomen, behaves differently depending on where it is found in the body, according to new research.

Scientists studied cases of leiomyosarcoma—which affects smooth muscle cells, found in the walls of hollow organs like the stomach, intestines, uterus and blood vessels—and found major differences in patient outcomes between tumor sites.

Leiomyosarcomas of the uterus, urinary tract and trunk had the poorest survival rates, compared with cancers of the limbs, head and neck, and male reproductive tract.

The findings indicate that tumor location could provide clinically meaningful information on disease risk for those with leiomyosarcoma, beyond cancer stage and grade, experts say.

Leiomyosarcoma is the most common type of soft tissue sarcoma—cancer that starts in tissues such as muscle, fat and blood vessels—but has limited treatment options and poor outcomes for many patients.

It affects smooth muscle cells, also known as involuntary muscles, which cause organs to contract without conscious control. Although tumors can develop throughout the body, they are commonly grouped simply as uterine or nonuterine disease.

University of Edinburgh scientists studied 11,700 patients with the condition, providing the most comprehensive assessment to date of survival across leiomyosarcoma arising at different locations in the body.

They also found that Black patients, those from lower-income households and widowed individuals experienced significantly poorer outcomes, highlighting the important contribution of socioeconomic factors to survival differences.

The study also identified differences in the underlying biology of tumors in different locations. For example, uterine tumors were more likely to have a specific genetic mutation compared with those found elsewhere in the body.

Clinical trials of leiomyosarcoma are often performed without accounting for where the cancer arises in the body. The findings suggest it may be important to account for tumor location when analyzing studies of new therapies, experts say.

The results also provide evidence that leiomyosarcoma tumors at different anatomical sites are biologically distinct and could support the development of more personalized approaches to treatment and management of the condition, they add.

The study was published in the Journal of the National Cancer Institute. The research team also included scientists from the Edinburgh Cancer Center, Beatson West of Scotland Cancer Center and the University of Glasgow.

Dr. Robb Hollis, study lead from the University of Edinburgh's Institute of Genetics and Cancer, said, "This study provides us with important knowledge about how leiomyosarcoma behaves differently depending on where it occurs in the body, both in terms of patient survival and the underlying biology of the disease. This information is critical for designing and interpreting future studies that seek to identify new treatment options for leiomyosarcoma patients."

Dr. Catherine Elliott, Cancer Research UK's director of research, said, "This study shows why our investment into rare cancers is key. It highlights how research can uncover critical differences between tumors, which is vital for developing more effective, personalized treatments for patients."

Publication details

Ailsa J Oswald et al., Leiomyosarcoma survival across anatomical sites identifies high-risk and low-risk patient groups to inform clinical trial design, JNCI: Journal of the National Cancer Institute (2026). DOI: 10.1093/jnci/djag284

Journal information: Journal of the National Cancer Institute

Clinical categories

Oncology

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Location of rare cancer impacts survival, study suggests (2026, October 26) retrieved 26 October 2026 from https://medicalxpress.com/news/2026-10-rare-cancer-impacts-survival.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com